Published : May-2020
No. of Pages : 145
1.1 List of Tables
1.2 List of Figures
2 DES: Executive Summary
2.1 Launch of New Pipeline Products and Increasing Prevalence of DES Are Expected to Drive the DES Market Forward
2.2 Pipeline Products with Distinct MOAs Are Likely to Help Companies to Tackle the DES Market
2.3 New Pipeline Products Will Help in Partially Addressing Some Unmet Needs
2.4 Companies Are Undertaking Strategic Deals in Anticipation of Maximizing Sales of DES Products
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Disease Classification
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Forecast Assumptions and Methods - Total and Diagnosed Prevalent Cases of DES
5.4.4 Forecast Assumptions and Methods - Total and Diagnosed Prevalent Cases of DES by Severity
5.5 Epidemiological Forecast for DES (2018-2028)
5.5.1 Diagnosed Prevalent Cases of DES
5.5.2 Age-Specific Diagnosed Prevalent Cases of DES
5.5.3 Sex-Specific Diagnosed Prevalent Cases of DES
5.5.4 Diagnosed Prevalent Cases of DES by Severity
5.5.5 Total Prevalent Cases of DES
5.5.6 Total Prevalent Cases of DES by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook
12 Appendix
List of Tables
Table 1: DES: Key Metrics in the 9MM
Table 2: Risk Factors and Comorbidities for DES
Table 3: Diagnostic Tests for DES
Table 4: Popular Validated Questionnaires for DES
Table 5: Treatment Guidelines for DES
Table 6: Country Profile - US
Table 7: Country Profile - 5EU
Table 8: Country Profile - Japan
Table 9: Country Profile - China
Table 10: Country Profile - India
Table 11: Leading Treatments for DES, 2018
Table 12: Comparison of Therapeutic Classes in Development for DES, 2018-2028
Table 13: Allergan's DES Portfolio Assessment, 2018
Table 14: Aldeyra's DES Portfolio Assessment, 2018
Table 15: Aurinia's DES Portfolio Assessment, 2018
Table 16: Kala's DES Portfolio Assessment, 2018
Table 17: Mitotech's DES Portfolio Assessment, 2018
Table 18: Novaliq's DES Portfolio Assessment, 2018
Table 19: Novartis' DES Portfolio Assessment, 2018
Table 20: Oyster Point Pharma's DES Portfolio Assessment, 2018
Table 21: RegeneRX's DES Portfolio Assessment, 2018
Table 22: Santen's DES Portfolio Assessment, 2018
Table 23: Senju's DES Portfolio Assessment, 2018
Table 24: Sun's DES Portfolio Assessment, 2018
Table 25: DES Market - Global Drivers and Barriers, 2018-2028
Table 26: Key Events Impacting Sales for DES in the US, 2018-2028
Table 27: DES Market - Drivers and Barriers in the US, 2018-2028
Table 28: Key Events Impacting Sales for DES in the 5EU, 2018-2028
Table 29: DES Market - Drivers and Barriers in the 5EU, 2018-2028
Table 30: Key Events Impacting Sales for DES in Japan, 2018-2028
Table 31: DES Market - Global Drivers and Barriers in Japan, 2018-2028
Table 32: Key Events Impacting Sales for DES in China, 2018-2028
Table 33: DES Market - Global Drivers and Barriers in China, 2018-2028
Table 34: DES Market - Global Drivers and Barriers in India, 2018-2028
Table 35: Key Historical and Projected Launch Dates for DES
Table 36: Key Historical and Projected Patent Expiry Dates for DES
Table 37: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for DES in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in DES During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for DES During the Forecast Period
Figure 4: Vicious Circle of DES
Figure 5: Classification of DES
Figure 6: 9MM, Diagnosed Prevalence of DES, Men and Women, %, Ages ?18 Years, 2018
Figure 7: 9MM, Total Prevalence of DES, Men and Women, %, Ages ?18 Years, 2018
Figure 8: 9MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of DES
Figure 9: 9MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of DES
Figure 10: 9MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of DES
Figure 11: 9MM, Sources Used to Forecast the Severity of Total Prevalent Cases of DES
Figure 12: 9MM, Diagnosed Prevalent Cases of DES, N, Both Sexes, Ages ?18 Years, 2018
Figure 13: 9MM, Diagnosed Prevalent Cases of DES by Age, N, Both Sexes, 2018
Figure 14: 9MM, Diagnosed Prevalent Cases of DES by Sex, N, Ages ?18 Years, 2018
Figure 15: 9MM, Diagnosed Prevalent Cases of DES by Severity, N, Ages ?18 Years, 2018
Figure 16: 9MM, Total Prevalent Cases of DES, N, Both Sexes, Ages ?18 Years, 2018
Figure 17: 9MM, Total Prevalent Cases of DES by Severity, N, Ages ?18 Years, 2018
Figure 18: Unmet Needs and Opportunities in DES
Figure 19: Products in Clinical Development for DES, 2018
Figure 20: Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for DES in the 9MM During the Forecast Period
Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of DES During the Forecast Period
Figure 22: Analysis of the Company Portfolio Gap in DES During the Forecast Period
Figure 23: Number of Deals in DES Market in the 9MM in Prior Years (2005-2019)
Figure 24: Global (9MM) Sales Forecast by Country for DES in 2018 and 2028
Figure 25: Sales Forecast by Drug Class for DES in the US, 2018 and 2028
Figure 26: Sales Forecast by Class for DES in the 5EU in 2018 and 2028
Figure 27: Sales Forecast by Class for DES in Japan in 2018 and 2028
Figure 28: Sales Forecast by Class for DES in China in 2018 and 2028
Figure 29: Sales Forecast by Class for DES in India in 2018 and 2028
